Hye Ryun Kim

Research interests

Publications

• Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.23.01017

• Regional Aβ-tau interactions promote onset and acceleration of Alzheimer’s disease tau spreading

  Neuron · 2022 · https://doi.org/10.1016/j.neuron.2022.03.034

• Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

  Immune Network · 2022 · https://doi.org/10.4110/in.2022.22.e2

• Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02212

• Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.07.035

• Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.06.004

• Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

  Journal of Hepatology · 2020 · https://doi.org/10.1016/j.jhep.2020.08.010

• Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00793

• Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00505

• Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer

  Genome Medicine · 2020 · https://doi.org/10.1186/s13073-020-00722-9

• Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

  Experimental & Molecular Medicine · 2020 · https://doi.org/10.1038/s12276-020-00493-8

• Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30504-2

• Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

  International Journal of Radiation Oncology*Biology*Physics · 2019 · https://doi.org/10.1016/j.ijrobp.2019.08.047

• Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1810171

• CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.77.9363

• Prevalence and prognostic implications of psychological distress in patients with gastric cancer

  BMC Cancer · 2017 · https://doi.org/10.1186/s12885-017-3260-2

• Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.71.3701

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1612674

• PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients

  Scientific Reports · 2016 · https://doi.org/10.1038/srep36956

• Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

  Lung Cancer · 2016 · https://doi.org/10.1016/j.lungcan.2016.05.001

• Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

  Oncotarget · 2016 · https://doi.org/10.18632/oncotarget.6874

• Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.43.8622

• Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

  Cancer · 2011 · https://doi.org/10.1002/cncr.26311

• Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases

  Annals of Oncology · 2008 · https://doi.org/10.1093/annonc/mdn026

• RUNX3 Suppresses Gastric Epithelial Cell Growth by Inducing p21WAF1/Cip1 Expression in Cooperation with Transforming Growth Factor β-Activated SMAD

  Molecular and Cellular Biology · 2005 · https://doi.org/10.1128/mcb.25.18.8097-8107.2005

Current projects

No projects listed.